Am I eligible for GLP-1 coverage? 2026 checker

The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027) covers Wegovy (injection and tablet), the Zepbound KwikPen, and Foundayo at a flat $50 per month — but only for weight management. It does NOT cover Ozempic, Mounjaro, or Rybelsus. And here is the part people miss: having type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease disqualifies you from the Bridge, because those are already covered Part D indications, so Medicare routes you to your Part D plan instead. The checker above walks you through it.

No. Manufacturer copay/savings cards are barred by federal law from being used with any government insurance — Medicare, Medicaid, or a government plan. They only work with commercial (employer or marketplace) insurance. On Medicare, your routes are the GLP-1 Bridge (if eligible), your Part D benefit (for a covered diabetes indication), or self-pay.

TrumpRx.gov is a federal self-pay portal that lists direct-from-manufacturer cash prices — roughly $199/month for Ozempic and the Wegovy pen, $149 for the Wegovy pill, and $299 for Zepbound at starting doses, rising toward ~$350 at maintenance. Yes, you still need a prescription; the portal does not prescribe or dispense, it routes you to the manufacturer program. It is most useful if you are uninsured or your plan excludes weight-loss drugs.

Among FDA-approved options, federal/manufacturer self-pay (TrumpRx.gov, LillyDirect, NovoCare) is the realistic route, roughly $149–$350/month depending on drug and dose. Compounded semaglutide or tirzepatide through telehealth is usually cheaper still (often from about $69/month) but is not an FDA-approved finished product, so the FDA does not review it for safety, efficacy, or quality — a trade-off to weigh carefully.